BACKGROUND _ AIMS: Some studies have reported a high incidence of @entity130 in 60%-80% of subjects who take nonselective nonsteroidal anti-inflammatory drugs and PPIs simultaneously. We performed a randomized, double-blind, controlled study to determine whether @entity7369 inhibitors (PPIs) exacerbate nonsteroidal anti-inflammatory drug-induced @entity130 . METHODS: Fifty-seven healthy subjects were randomly assigned groups given the @entity2247  inhibitor @entity12698 (200 mg, twice daily) plus placebo for 2 weeks ( @entity2247  + placebo group, n  = 30), or @entity12698 plus the PPI @entity34070 (20 mg, once daily) for 2 weeks ( @entity2247  + PPI group, n  = 27). The study was performed from October 2012 through September 2013 at a tertiary medical center in Japan. All subjects were evaluated by capsule endoscopy at the start of the study and then after 2 weeks administration of @entity12698 with @entity34070 or placebo. The incidence rates and the numbers of @entity130 ( @entity1066 ) that were observed under capsule endoscopy were compared between groups. The primary endpoint was the incidence of @entity3137 at the second capsule endoscopy examination. RESULTS: A significantly higher proportion of subjects in the @entity2247  + PPI group developed @entity130 (12 of 27 subjects; 44.4%) than in the @entity2247  + placebo group (5 of 30 subjects; 16.7%; P  = .04). Subjects in the @entity2247  + PPI group had a significant increase in risk of @entity130 compared with the @entity2247  + placebo group (relative risk, 2.67; 95% confidence interval, 1.08-6.58). The number of @entity2681 in each member of the @entity2247  + PPI group was greater than  in each member of the @entity2247  + placebo group (P  = .02). The number of @entity1066 did not differ between groups. Twenty-six percent of subjects in the @entity2247  + PPI group developed @entity3137 in the jejunum, compared with none of the subjects in the @entity2247  + placebo group (P  = .003); no such trend was found in the ileum. CONCLUSIONS: In a randomized, controlled trial, PPIs increased the risk of short-term nonsteroidal anti-inflammatory drug-induced @entity130 . UMIN clinical trial registry number: UMIN000008883.

@entity7369 Inhibitors Increase Incidence of Nonsteroidal Anti-Inflammatory Drug-Induced XXXX : A  Randomized, Placebo-Controlled Trial.

@entity12698 :: ('MESH:C105934', 'Chemical') :: ['celecoxib'] @entity34070 :: ('MESH:D064750', 'Chemical') :: ['rabeprazole'] @entity7369 :: ('479', 'Gene') :: ['proton pump'] @entity2681 :: ('MESH:D014077', 'Disease') :: ['erosions'] @entity1066 :: ('MESH:D014456', 'Disease') :: ['ulcers and erosions', 'ulcers'] @entity2247 :: ('4513', 'Gene') :: ['cyclooxygenase (COX) 2', 'COX-2'] @entity3137 :: ('MESH:D009059', 'Disease') :: ['mucosal injuries', 'mucosal injury'] @entity130 :: ('MESH:D014947', 'Disease') :: ['small bowel injury', 'small bowel injuries']
@entity130 :: (MESH:D014947,Disease) :: ['Small Bowel Injury']
